Tubulis GmbH
acquired by Gilead Sciences6 known investors
Germany-based clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) for oncology, acquired by Gilead Sciences for $3.15 billion upfront plus up to $1.85 billion in contingent payments.